**Leptotrichia Bacteremia in Patients Receiving High-Dose Chemotherapy**

Marc Roger Couturier, E. Susan Slechta, Claudia Goulston, Mark A. Fisher, and Kimberly E. Hanson

**MATERIALS AND METHODS**

**Clinical isolates.** The Associated Regional and University Pathologists (ARUP) laboratories database was searched for all isolates identified as *Leptotrichia* spp. between January 2005 and December 2010. Specimen source, Gram stain result, the presence or absence of growth on solid media, and antimicrobial susceptibility patterns (when available) were recorded. ARUP is a national reference laboratory that also operates as the primary microbiology laboratory for the University of Utah Health Care (UUHC) system. Isolated organisms were submitted from outside institutions within the United States for molecular identification, whereas UUHC organisms were identified from primary clinical specimens. Medical records were reviewed for UUHC patients, under a protocol approved by the University of Utah Institutional Review Board. The following clinical information was assessed for adult patients: past medical history, presenting signs and/or symptoms of infection, diagnostic imaging, microbiology results, and antimicrobial therapies.

**Blood culture.** UUHC patient blood samples were inoculated into one Bactec Plus aerobic bottle (resin media) and a Bactec standard anaerobic bottle (BD, Franklin Lakes, NJ). Cultures were incubated for 5 days in a Bactec 9240 blood culture system (BD) and were monitored automatically every 10 min for the presence of microbial growth. All positive anaerobic blood cultures were analyzed by Gram stain and subcultured on two sheep blood agar plates every 10 min. Plates were incubated for 10 days, and colonies were identified by ARUP Laboratories.

**High-dose chemotherapy** followed by hematopoietic stem-cell transplantation (HSCT), is a well-established treatment modality for a variety of hematologic malignancies; however, infectious complications remain a major barrier to the overall success of this procedure. HSCT recipients are at particularly high risk for the development of invasive bacterial infections as a result of regimen-related neutropenia and cytotoxic damage to the oral and gastrointestinal mucosa. Mucositis severity, specifically, is an independent predictor of anaerobic bloodstream infection (BSI) following HSCT (11).

*Leptotrichia* spp. are fastidious anaerobic, pencil-shaped, Gram-negative rods that reside in the mouths, intestines, and female genital tracts of humans (20). Traditionally considered to be nonpathogenic, *Leptotrichia* species have occasionally been reported to cause invasive disease in HSCT patients and other immunocompromised hosts (6, 14, 18). The overall incidence of *Leptotrichia* infections in at-risk patient populations, however, may be underestimated. These organisms are notoriously difficult to recover from blood culture and may retain crystal violet, which can lead to their misidentification as Gram-positive rods. Commercially available phenotypic identification systems also have problems classifying these organisms (12). We routinely used 16S rRNA partial gene sequencing for the identification of anaerobic bacteria (16), which allowed us to recognize an increase in the number of *Leptotrichia* isolates identified by our laboratory. The purpose of the present study was to evaluate the incidence of *Leptotrichia* infections identified by ARUP Laboratories over a 5-year period and to review the occurrence of this infection at our institution.

(A portion of these data were presented at the 2010 American Society for Microbiology meeting in San Diego, CA, and at the 2010 Infectious Disease Society of America meeting in Vancouver, British Columbia, Canada.)
software for Microsoft Excel (version 2.26). The proportions of patients joining method with 500 bootstrap replications with MEGA5 software.

A multiple sequence alignment of our isolates were performed in accordance with the CLSI guidelines (3). For the pres- ence study, Leptotrichia was identified to the species level, with L. trevisanii being the most frequently encountered species (47% [32/68]). The remaining species-level identifications included six isolates each of L. wadei, L. goodfellowii, and L. hongkongensis. One isolate that failed to grow on initial plating was repeatedly subcultured to several broth (Bactec standard anaerobic blood agar) and solid (Columbia sheep blood, chocolate, and Brucella blood + hemin + vitamin K) media but was found to grow only in broth containing human blood. Only one multiple myeloma patient in the UUHC cohort had L. honkongensis suc- cessfully subcultured from their blood culture bottle to chocolate agar.

Antimicrobial susceptibility testing was performed for 39 isolates (Table 1). The majority appeared highly susceptible to the antibiotics tested, and there was no obvious difference in susceptibility patterns for a particular species. However, two L. trevisanii isolates displayed metronidazole MICs greater than 32 μg/ml, and
one of these isolates also had a cefoxitin MIC of 32 μg/ml. A single isolate of L. goodfellowii also had an MIC of 16 for metronidazole. None of the tested organisms possessed detectable β-lactamase activity.

Clinical case histories. In all, 14 cases of Leptotrichia BSI were identified from 13 unique UUHC patients. Approximately a third of cases (36% [5/14]) were part of polymicrobial bacteremias involving other pathogens (i.e., Enterococcus faecium, viridans group Streptococcus, Streptococcus infantis, Bacteroides urealyticus, or Fusobacterium nucleatum). All UUHC patients had received high-dose chemotherapy immediately prior to the onset of bacteremia; twelve had hematological cancers, and one was being treated for a solid tumor malignancy.

More than half of the UUHC hematology patients (67% [8/12]) were undergoing autologous HSCT (auto-HSCT) specifically for the treatment of multiple myeloma. Patients in the myeloma cohort had all been treated with a melphalan-based induction regimen that also included the novel chemotherapeutic agents thalidomide and bortezomib. L. hongkongensis was the most common single species identified from multiple myeloma patients (63%, 5/8). However, the test for association between L. hongkongensis and myeloma chemotherapy for auto-HSCT did not reach statistical significance (P = 0.4).

The multiple myeloma subgroup presented with similar clinical signs and symptoms of infection. All were neutropenic and had fever that was associated with nausea, vomiting, diarrhea, and abdominal pain despite prophylactic oral levofloxacin and fluconazole. In addition, two patients were hemodynamically unstable at the time of hospital admission: one grew L. hongkongensis and viridans group Streptococcus, and the other had L. hongkongensis identified by sequencing directly from the blood culture broth. Of note, one of the hypotensive patients experienced two separate episodes of L. hongkongensis bacteremia following tandem auto-HSCT separated by 3 months. Several myeloma patients (3/8) had computerized axial tomography confirmed necrotizing enterocolitis with negative Clostridium difficile enzyme immunoassay testing from stool specimens. L. hongkongensis was identified in the blood of two of these patients, and L. wadei was isolated from the third. All of the patients in this cohort survived their respective episodes of Leptotrichia BSI, with negative repeat blood cultures following the initiation of empirical meropenem as per our institution’s protocol for the management of neutropenic fever.

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Modal MIC (μg/ml)</th>
<th>MIC range (μg/ml)</th>
<th>No. of isolates tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampicillin/sulbactam</td>
<td>&lt;0.5/0.25</td>
<td>≤0.5/0.2–1/0.5</td>
<td>39</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>&lt;1</td>
<td>&lt;1–32</td>
<td>39</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>&lt;0.5</td>
<td>&lt;0.5–2</td>
<td>38</td>
</tr>
<tr>
<td>Meropenem</td>
<td>&lt;0.25</td>
<td>&lt;0.25</td>
<td>39</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>1</td>
<td>≤0.5–≤32</td>
<td>39</td>
</tr>
<tr>
<td>Penicillin</td>
<td>&lt;0.06</td>
<td>≤0.06–0.5</td>
<td>39</td>
</tr>
<tr>
<td>β-Lactamase</td>
<td>Negative</td>
<td>Negative</td>
<td>38</td>
</tr>
</tbody>
</table>

*The Leptotrichia species distribution included 21 L. trevisanii, 4 L. wadei, and 4 L. goodfellowii isolates and 10 isolates that could not be identified to the species level.
*There are currently no established interpretive breakpoints for Leptotrichia spp.
*Clindamycin susceptibility was performed upon specific request.
The remaining five UUHC patients from were receiving therapy for acute myelogenous leukemia (AML) (n = 2), acute lymphoblastic leukemia (n = 1), T-cell-rich large B-cell lymphoma (n = 1), and esophageal cancer (n = 1). Both of the AML patients received allogeneic HSCT, while the lymphoma patient received auto-HSCT. All five patients presented initially for the evaluation of neutropenic fever; however, only the hematology patients had received prophylactic antimicrobials. At the time of hospital admission, all five had severe oral mucositis and were treated empirically with meropenem with or without vancomycin. Unlike the multiple myeloma cohort, only one patient exhibited diarrhea, which was negative by both enteric stool culture and PCR for C. difficile. The L. trevisanii species identified in these patients were variable, with two unspeciated isolates and one of each L. hongkongensis, L. trevisanii, and L. goodfellowii. Like the multiple myeloma cohort, these patients all survived these episodes of bacteremia.

DISCUSSION

Anaerobic BSIs have increasingly been recognized as an important sequel of high-dose chemotherapy, with severe alimentary tract mucositis identified as a predisposing risk-factor (11). While members of the genus Leptotrichia have been isolated from neutropenic patients (1, 6, 12–14, 19), they likely remain an underappreciated cause of BSI due to inherent difficulties with conventional laboratory identification methods (12).

We observed an increase in invasive Leptotrichia infections at ARUP in 2007, followed by a subsequent rise in our own hospital in 2008. The reasons for this are probably multifactorial. First, regular use of 16S rRNA partial gene sequencing significantly expands the number of anaerobic organisms that can be accurately identified (10, 16). It is also well recognized that Leptotrichia are not reliably identified by a commonly used phenotypic identification system (Rapid ANA II; Remel, Lenexa, KS) (12, 14). Furthermore, the number of at-risk patients has also expanded in recent years with the routine use of high-dose cytotoxic chemotherapy for HSCT and the treatment of other malignancies. In recognition of the increasing numbers of auto-HSCT patients admitted with severe mucositis, enteric bacteremia, and sepsis, anaerobic prophylactic strategies were revisited at our institution in 2009. These revisions may account for the subsequent decline in Leptotrichia infections from our transplant center in 2010 (Fig. 1).

Although not generally regarded as drug-resistant organisms, Leptotrichia antimicrobial susceptibility patterns are largely undefined. Our data suggest that these organisms remain highly susceptible to standard agents. Some of the drugs used routinely for prophylaxis or empirical treatment of neutropenic fever, however, lack robust anaerobic activity (e.g., levofloxacin, cefepime, or cefazidine). Patients with neutropenic oral mucositis and/or enterocolitis are at increased risk for anaerobic infection and should therefore be treated with a broad-spectrum antimicrobial regimen that has anaerobic coverage (9).

Seven Leptotrichia species have been validly described. Of these, L. buccalis and L. goodfellowii were implicated in severe infections, including endocarditis, L. trevisanii, L. wadei, and L. hongkongensis were associated with bacteremia, and L.hofstadii and L. shahii have been isolated from oral wounds (2, 7, 8, 21). It is interesting that, although previously only described as a cause of BSI in two cases (6, 18), L. trevisanii accounted for half of our isolates (32/68 [48%]). It is unclear whether this organism has been regularly identified at other institutions but not reported or whether it is simply not as pathogenic as other species (e.g., L. goodfellowii and L. buccalis). In addition, we identified multiple isolates only to the genus level despite high-quality sequencing results. The phylogenetic analysis does not cluster these isolates within any of the currently described species (Fig. 2), suggesting that some of these organisms may in fact represent previously undescribed species.

Of particular interest was the identification of six cases of L. hongkongensis bacteremia in our UUHC cohort, five of which were isolated from multiple myeloma patients. Although the apparent association between L. hongkongensis and auto-HSCT for multiple myeloma did not reach statistical significance, likely due to our small sample size, the observation is clinically important. L. hongkongensis was only recently described and to date, limited information exists on the clinical spectrum of associated illness (21). Four of the L. hongkongensis sequences in the present study were identical to the type strain (GenBank accession no. EU919515, listed as Leptotrichia sp. strain HKU24) (21), and two were identical to a Leptotrichia sp. isolated from the blood of a patient undergoing treatment for AML (GenBank accession no. AF189244) (12) (Fig. 2). These two clusters of L. hongkongensis sequences were 99.8% identical (differing by only 2 bp) to each other, which suggests that the organism in Patel et al. (12) was most likely L. hongkongensis. Consistent with this notion is the fact that their isolate also failed to grow on initial subculture to multiple solid media. The Patel et al. report (12), in addition to our six cases of bacteremia with L. hongkongensis in a single BMT unit, suggests that this species may be of particular concern in patients undergoing high-dose chemotherapy for HSCT, and its presence may be suggested by the characteristic Gram stain and failure to grow on subculture to solid media. Widespread recognition of these clinical and laboratory observations may lead to better understanding of the incidence of this organism.

In conclusion, Leptotrichia spp. are emerging pathogens in neutropenic patients receiving high-dose chemotherapy. At our institution, there was an apparent association between Leptotrichia BSI and the chemotherapeutic agents used for multiple myeloma patients undergoing auto-HSCT. In particular, L. hongkongensis was shown to be the predominant species in this population, further defining the clinical relevance of this recently described species. Molecular methods have greatly improved the clinical laboratories’ ability to identify these potential pathogens, which have fortunately remained susceptible to most antimicrobial agents.

ACKNOWLEDGMENTS

We thank Mary Lampas and Stephanie Sanders for assistance with the medical record review. We thank Keith E. Simmons for his review of these data. We also thank the clinical microbiology laboratory at ARUP for providing antimicrobial susceptibility testing.

REFERENCES